Skip to main content
. 2018 Jul 3;5:195. doi: 10.3389/fmed.2018.00195

Figure 1.

Figure 1

tPA administration drives hemovascular dysfunction. Thrombolytic therapy in the acute phase of ischemic stroke promotes activation not only of the fibrinolytic pathway but also coagulation, complement and contact phase systems. FDPs, fibrin degradation products; HMWK, high molecular weight kininogen; tPA, tissue-type plasminogen activator.